Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/23/2025 | $6.00 | Mkt Outperform | Citizens JMP |
| 3/27/2024 | $1.40 → $10.00 | Hold → Buy | Jefferies |
| 3/26/2024 | $5.00 | Neutral → Buy | BTIG Research |
| 1/6/2023 | $5.00 → $2.00 | Buy → Hold | Jefferies |
| 8/2/2022 | $8.00 → $2.50 | Outperform → Market Perform | BMO Capital Markets |
| 8/2/2022 | Buy → Neutral | BTIG Research | |
| 5/4/2022 | $14.00 | Buy | H.C. Wainwright |
| 10/15/2021 | $16.00 | Buy | BTIG Research |
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable response rates and brain-penetrant efficacy across different lines of therapy The safety and tolerability of IBTROZI have been well established in the pivotal program, with one of the largest safety datasets in ROS1+ NSCLC showing a favorable and consistent profile Company to host conference call tomorrow, June 12 at 7:30 a.m. EDT Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (
Presentation will highlight the comparable efficacy and safety of taletrectinib across pivotal studies and different ethnicities and world regions The drug is under Priority Review by the U.S. Food and Drug Administration (FDA) and has a Prescription Drug User Fee Act (PDUFA) date of June 23, 2025 Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results from TRUST-I and TRUST-II, its pivotal Phase 2 clinical studies on the efficacy and safety of taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), will be presented at the upcomin
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at three upcoming investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 3:00 p.m. ET in New York, NY 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 p.m. ET in New York, NY TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
8-K - Nuvation Bio Inc. (0001811063) (Filer)
8-K - Nuvation Bio Inc. (0001811063) (Filer)
SCHEDULE 13G/A - Nuvation Bio Inc. (0001811063) (Subject)
Citizens JMP initiated coverage of Nuvation Bio with a rating of Mkt Outperform and set a new price target of $6.00
Jefferies upgraded Nuvation Bio from Hold to Buy and set a new price target of $10.00 from $1.40 previously
BTIG Research upgraded Nuvation Bio from Neutral to Buy and set a new price target of $5.00